<DOC>
	<DOC>NCT02595073</DOC>
	<brief_summary>Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis</brief_summary>
	<brief_title>Clinical Study to Evaluate the Efficacy and Safety of DSXS With Atopic Dermatitis</brief_title>
	<detailed_description>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>male and nonpregnant females, age 6 months or older, with a confirmed diagnosis of moderate to severe AD Lacks stable diagnosis of atopic dermatitis or has been diagnosed with mild atopic dermatitis.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>